SCHEMBL4046539

SCHEMBL4046539

COc1cccc(Nc2nc(N)n(-c3nccs3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP1B1 Q16678 1/20 0.49
EGFR P00533 1/20 0.48
FLT3 P36888 6/20 0.47
KIT P10721 2/20 0.47
AURKA O14965 1/20 0.47
JAK2 O60674 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
ROCK1 Q13464 1/20 0.47
AXL P30530 1/20 0.45
PIK3CA P42336 2/20 0.45
PIK3CG P48736 2/20 0.45
PIK3CB P42338 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
POLB P06746 1/20 0.44
SYK P43405 1/20 0.43
KCNH3 Q9ULD8 1/20 0.43
CDK2 P24941 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043372 0.89 ZAP70 (0.50) CYP1A1CYP1A2CYP1B1FLT3KIT
SCHEMBL4037206 0.86 FLT3 (0.46) FLT3KITAURKAJAK2IRAK4
SCHEMBL4039047 0.85 SYK (0.58) FLT3KITAURKAJAK2IRAK4
SCHEMBL4044502 0.83 FLT3 (0.65) FLT3KITAURKAJAK2IRAK4
SCHEMBL4037162 0.82 FLT3 (0.49) FLT3KITAURKAJAK2IRAK4
SCHEMBL4043844 0.82 FLT3 (0.49) FLT3KITAURKAJAK2IRAK4
SCHEMBL4036635 0.82 PLK1 (0.45) CYP1A2EGFRFLT3KITAURKA
SCHEMBL4039114 0.81 SRC (0.56) CYP1A1CYP1A2CYP1B1FLT3KIT
SCHEMBL4038754 0.81 FLT3 (0.53) FLT3KITAURKAJAK2IRAK4
SCHEMBL4041779 0.80 FLT3 (0.72) EGFRFLT3KITAURKAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 CYP1A1 4281/4885CYP1A2 3941/4885CYP1B1 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.